ArticleAIDS and behavior2026
Chemsex Practice Among PrEP Users in Buenos Aires, Argentina.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chemsex, defined as the intentional use of psychoactive substances to enhance sexual activity, has been associated with a higher frequency of sexually transmitted infections (STIs) diagnosis among HIV pre-exposure prophylaxis (PrEP) users. Evidence from Latin America remains limited. This research aims to characterize the practice of chemsex and STIs prevalence in PrEP users in Buenos Aires, Argentina. We conducted a descriptive, cross-sectional study using clinical records and a self-administered ad-hoc questionnaire among PrEP users attending four public hospitals. Between February to October 2024, 165 PrEP users were included. The prevalence of chemsex, during the previous year, was 32%. The drugs used, in order of frequency, were MDMA 21%; cocaine 14%; gamma-hydroxybutyrate 12%; ketamine 10%; methamphetamine 6%; mephedrone 2%; and gamma-butyrolactone 1%. Additionally, 48% reported concurrent use of two or more drugs during the practice. A multivariate logistic regression analysis showed that engaging in chemsex was significantly associated with higher odds of reporting an STI in the past year [aOR 3.67 (95% CI 1.67 - 8.42) p 0.001). Age, time on PrEP, number of sexual partners, and engagement in group sex were not independently associated with STI diagnosis. In conclusion, chemsex was common among PrEP users in Buenos Aires and independently associated with recent STI diagnosis, highlighting the importance of integrating behavioral assessments and harm reduction strategies into PrEP and sexual health policymaking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.